Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.86 |
| ▸ | MAPT | P10636 | 4/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.86 |
| ▸ | MEN1 | O00255 | 3/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | HPGD | P15428 | 1/20 | 0.86 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.86 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | TAS2R38 | P59533 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11326932 | 0.81 | GAA (0.60) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19891237 | 0.81 | GAA (0.60) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3041278 | 0.81 | POLB (0.61) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19891235 | 0.81 | ALDH1A1 (0.60) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19891238 | 0.81 | GAA (0.60) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL24534286 | 0.80 | HTT (0.68) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL17465537 | 0.80 | HTT (0.68) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19891039 | 0.80 | HTT (0.68) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19891157 | 0.80 | ALDH1A1 (0.58) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL15946364 | 0.79 | ALDH1A1 (0.63) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115449136-A | Accelerator composition of rubber nanocomposite and preparation method and application thereof | 浙江大学 | 2022-12-09 | — | — | CN | claimed |
| CN-115449136-B | Accelerator composition of rubber nanocomposite as well as preparation method and application thereof | 浙江大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-115449136-A | Accelerator composition of rubber nanocomposite and preparation method and application thereof | 浙江大学 | 2022-12-09 | — | — | CN | disclosed |
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-03-05 | — | — | US | disclosed |
| US-10253256-B2 | Use of sulfur and selenium compounds as precursors to nanostructured materials | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-04-09 | — | — | US | disclosed |
| WO-2018035291-A1 | 1,2,4-TRIAZOLIDINE-3-THIONE DERIVATIVES AND USES THEREOF | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-02-22 | — | — | WO | disclosed |
| US-9464064-B2 | HCV helicase inhibitors and methods of use thereof | UNIVERSITY OF KANSAS (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160237345-A1 | USE OF SULFUR AND SELENIUM COMPOUNDS AS PRECURSORS TO NANOSTRUCTURED MATERIALS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-08-18 | — | — | US | disclosed |
| EP-3049370-A1 | USE OF SULFUR AND SELENIUM COMPOUNDS AS PRECURSORS TO NANOSTRUCTURED MATERIALS | The Trustees of Columbia University in the City of New York (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| EP-1811342-B1 | USE OF A SULFUR-ATOM-CONTAINING COMPOSITION FOR FORMING OF LITHOGRAPHIC ANTIREFLECTION FILM | NISSAN CHEMICAL IND LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-7795369-B2 | Sulfur atom-containing anti-reflective coating forming composition for lithography | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20080118870-A1 | Sulfur Atom-Containing Anti-Reflective Coating Forming Composition For Lithography | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1811342-A1 | SULFUR-ATOM-CONTAINING COMPOSITION FOR FORMING OF LITHOGRAPHIC ANTIREFLECTION FILM | Nissan Chemical Industries, Ltd. (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| US-4990232-A | Photooxidation of N,N*-substituted thiourea | CIBA-GEIGY CORPORATION (US) | 1991-02-05 | — | — | US | disclosed |
| US-4159328-A | INSECTICIDES, MITICIDES | NIHON NOHYAKU CO., LTD. (JP) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | GAA 2409/4885KMT2A 938/4885MAPT 1952/4885 |
| US-10253256-B2 | Use of sulfur and selenium compounds as precursors to nanostructured materials | SCLY, TST, SOD1 | GAA 1399/4885KMT2A 4073/4885MAPT 601/4885 |
| US-20080118870-A1 | Sulfur Atom-Containing Anti-Reflective Coating Forming Composition For Lithography | TPMT, TST, TMT1A | GAA 4360/4885KMT2A 494/4885MAPT 1558/4885 |
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | RARB, RARG, RARA | GAA 1203/4885KMT2A 3906/4885MAPT 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.